Cocrystal Pharma, Inc.
COCP
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inā¦ read more
Healthcare
Biotechnology
14 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.08
Price-0.92%
-$0.01
1Y
Price
Market Cap
$14.891m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-981.3%
EBITDA Margin-1021.8%
Net Profit Margin-1040.0%
Free Cash Flow Margin-981.3%
EBITDA Margin-1021.8%
Net Profit Margin-1040.0%
Free Cash Flow MarginRevenue
$225k
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$8.829m
+0.0%
1y CAGR+17.4%
3y CAGR+26.5%
5y CAGREPS
-$0.74
+5.1%
1y CAGR+19.9%
3y CAGR+40.0%
5y CAGRBook Value
$4.116m
$7.426m
Assets$3.310m
Liabilities$1.424m
DebtDebt to Assets
19.2%
-0.2x
Debt to EBITDAFree Cash Flow
-$7.792m
+5.0%
1y CAGR+14.6%
3y CAGR+18.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company